These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 37981241)
1. Changes in buprenorphine waivered provider supply after Virginia Medicaid implements the addiction and recovery treatment services program and Medicaid expansion. Urmi AF; Britton E; Saunders H; Harrell A; Bachireddy C; Lowe J; Barnes AJ; Cunningham P J Subst Use Addict Treat; 2024 Feb; 157():209213. PubMed ID: 37981241 [TBL] [Abstract][Full Text] [Related]
2. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761 [TBL] [Abstract][Full Text] [Related]
3. Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status. Sanmartin MX; Ali MM; Dwyer DS Subst Abus; 2022 Dec; 43(1):1072-1074. PubMed ID: 35442126 [No Abstract] [Full Text] [Related]
4. A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid. Saloner B; Landis RK; Jayakrishnan R; Stein BD; Barry CL Subst Abus; 2022; 43(1):682-690. PubMed ID: 35099362 [No Abstract] [Full Text] [Related]
6. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. Knudsen HK J Stud Alcohol Drugs; 2015 Jul; 76(4):644-54. PubMed ID: 26098042 [TBL] [Abstract][Full Text] [Related]
7. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Jones CM; McCance-Katz EF Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876 [TBL] [Abstract][Full Text] [Related]
8. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. Andrilla CHA; Moore TE; Patterson DG; Larson EH J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637 [TBL] [Abstract][Full Text] [Related]
9. Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply. Auty SG; Stein MD; Walley AY; Drainoni ML J Subst Abuse Treat; 2020 Aug; 115():108032. PubMed ID: 32600629 [TBL] [Abstract][Full Text] [Related]
10. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states. Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454 [No Abstract] [Full Text] [Related]
11. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Knudsen HK; Lofwall MR; Havens JR; Walsh SL Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356 [TBL] [Abstract][Full Text] [Related]
12. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees. Wen H; Hockenberry JM; Pollack HA JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185 [TBL] [Abstract][Full Text] [Related]
13. The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States. Stringfellow EJ; Lim TY; Dong H; Zhang Z; Jalali MS Addiction; 2023 Nov; 118(11):2215-2219. PubMed ID: 37434347 [TBL] [Abstract][Full Text] [Related]
14. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine. Andrilla CHA; Jones KC; Patterson DG J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634 [TBL] [Abstract][Full Text] [Related]
15. Treatment access for opioid use disorder among women with medicaid in Florida. Elmore AL; Patrick SW; McNeer E; Fryer K; Reid CN; Sappenfield WM; Mehra S; Salemi JL; Marshall J Drug Alcohol Depend; 2023 May; 246():109854. PubMed ID: 37001322 [TBL] [Abstract][Full Text] [Related]
16. Expanding Opioid Use Disorder Treatment in Priority Areas: The Role of Certified Nurse-Midwives. Kane C; Topmiller M J Midwifery Womens Health; 2022 May; 67(3):314-320. PubMed ID: 35506768 [TBL] [Abstract][Full Text] [Related]
17. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Ghertner R Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570 [TBL] [Abstract][Full Text] [Related]
18. Supply of buprenorphine waivered physicians: the influence of state policies. Stein BD; Gordon AJ; Dick AW; Burns RM; Pacula RL; Farmer CM; Leslie DL; Sorbero M J Subst Abuse Treat; 2015 Jan; 48(1):104-11. PubMed ID: 25218919 [TBL] [Abstract][Full Text] [Related]
19. The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia. Saloner B; Landis R; Stein BD; Barry CL Health Aff (Millwood); 2019 Apr; 38(4):633-642. PubMed ID: 30933592 [TBL] [Abstract][Full Text] [Related]
20. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. Andrilla CHA; Patterson DG J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]